Deutsche Bank Aktiengesellschaft Upgrades AstraZeneca (LON:AZN) to Hold

AstraZeneca (LON:AZN) was upgraded by investment analysts at Deutsche Bank Aktiengesellschaft to a “hold” rating in a research note issued to investors on Monday, Digital Look reports.

A number of other equities research analysts have also recently issued reports on AZN. Berenberg Bank reiterated a “buy” rating on shares of AstraZeneca in a research note on Wednesday, March 13th. BMO Capital Markets reiterated an “outperform” rating on shares of AstraZeneca in a research note on Monday, February 12th. Jefferies Financial Group reiterated a “hold” rating and set a £110 ($136.94) price objective on shares of AstraZeneca in a research note on Friday, February 16th. Shore Capital reiterated a “buy” rating on shares of AstraZeneca in a research note on Monday. Finally, JPMorgan Chase & Co. reiterated an “overweight” rating on shares of AstraZeneca in a research note on Thursday, April 4th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of £115.43 ($143.69).

AstraZeneca Price Performance

Shares of AZN opened at £109.20 ($135.94) on Monday. AstraZeneca has a 52-week low of GBX 9,461 ($117.78) and a 52-week high of £123.92 ($154.26). The company has a debt-to-equity ratio of 75.70, a quick ratio of 0.59 and a current ratio of 0.82. The stock has a 50 day simple moving average of £103.42 and a 200 day simple moving average of £104.22. The firm has a market capitalization of £169.26 billion, a PE ratio of 3,595.66, a P/E/G ratio of 0.89 and a beta of 0.19.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.